本文回顾性评价了非肌层浸润性膀胱癌患者TURBT术后3d连续膀胱灌注吡柔比星(THP)的疗效。1995年3月至2009年4月总计184例非肌层浸润性膀胱癌患者TURBT术后3d连续灌注THP(将30 mg THP溶解于40ml无菌注射用水中灌注)。单因素和多因素分析肿瘤的数量、大小、分级和临床分期与肿瘤复发的关系,中位随访时间为55.1个月。研究采用EAU指南对184例患者的肿瘤复发风险进 This article retrospectively evaluated the efficacy of continuous intravesical instillation of pirarubicin (THP) in patients with non-muscle invasive bladder cancer after TURBT. From March 1995 to April 2009 a total of 184 patients with non-muscle invasive bladder cancer were treated with THP (continuous infusion of 30 mg THP in 40 ml sterile water for perfusion) 3 days after TURBT. Univariate and multivariate analysis showed that the median follow-up time was 55.1 months for the relationship between the number, size, grade, clinical stage and tumor recurrence. Study using EAU guidelines 184 patients with tumor recurrence risk into